文献速递肿瘤 PET/CT

[68Ga]Ga-DOTA-FAPI-04 PET/CT评估胃癌:[18F]FDG PET/CT对比

[68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-04-25

纳入56例经组织学证实的胃癌患者(45例分期、11例术后再分期),每例均在1周内完成[18F]FDG与[68Ga]Ga-DOTA-FAPI-04 PET/CT。基于病灶分析,[68Ga]Ga-DOTA-FAPI-04在检出腹膜转移(159 vs. 47,P < 0.001)和骨转移(64 vs. 55,P = 0.003)上优于[18F]FDG,原发灶SUVmax(10.3 vs. 8.1,P = 0.004)和TBR(11.6 vs. 5.8,P < 0.001)更高;判断淋巴结状态时特异度和阳性预测值更高(100.0% vs. 97.7%,P < 0.001;100.0% vs. 57.1%,P = 0.001)。

要点

  • 基于病灶分析,[68Ga]Ga-DOTA-FAPI-04检出腹膜转移159个 vs. [18F]FDG 47个(P < 0.001),骨转移64个 vs. 55个(P = 0.003)。
  • 原发灶SUVmax 10.3 vs. 8.1(P = 0.004),TBR 11.6 vs. 5.8(P < 0.001),[68Ga]Ga-DOTA-FAPI-04更高。
  • 判断淋巴结状态时[68Ga]Ga-DOTA-FAPI-04特异度100.0% vs. 97.7%(P < 0.001),阳性预测值100.0% vs. 57.1%(P = 0.001)。

核心结论

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT能更好地评估原发性胃癌及腹膜、腹部淋巴结和骨转移。
  • [68Ga]Ga-DOTA-FAPI-04 PET/CT为复发疾病患者提供更多信息,并具有监测治疗反应的潜力。

研究设计与样本

  • 本研究纳入56例经组织学证实的胃癌患者,其中45例用于分期、11例用于术后再分期。
  • 每例患者均在1周内完成[18F]FDG与[68Ga]Ga-DOTA-FAPI-04 PET/CT检查。
  • 以组织学检查作为参考标准;若无法进行组织学诊断,随访数据(包括实验室检查和医学影像结果)也可作为参考。

主要发现

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT在检出原发肿瘤和淋巴结转移方面与[18F]FDG相当。
  • 基于病灶分析,[68Ga]Ga-DOTA-FAPI-04在检出腹膜转移(159 vs. 47,P < 0.001)和骨转移(64 vs. 55,P = 0.003)方面优于[18F]FDG。
  • 与原发肿瘤相比,[68Ga]Ga-DOTA-FAPI-04的SUVmax(10.3 vs. 8.1,P = 0.004)和TBR(11.6 vs. 5.8,P < 0.001)更高。
  • 在淋巴结受累(8.0 vs. 3.7,P < 0.001)和腹膜转移(8.1 vs. 3.2,P < 0.001)中,[68Ga]Ga-DOTA-FAPI-04的TBR高于[18F]FDG PET/CT。
  • 在判断淋巴结状态时,[68Ga]Ga-DOTA-FAPI-04的特异度和阳性预测值显著高于[18F]FDG(100.0% vs. 97.7%,P < 0.001;100.0% vs. 57.1%,P = 0.001)。

关键数值与推荐

  • [68Ga]Ga-DOTA-FAPI-04与[18F]FDG在评估N分期方面相当(47.1% vs. 23.5%,P = 0.282)。
  • [68Ga]Ga-DOTA-FAPI-04 PET/CT在所有再分期患者中检出更多阳性复发病灶,并显示更清晰的肿瘤勾画。
  • 2例患者在化疗后接受随访[68Ga]Ga-DOTA-FAPI-04 PET/CT扫描,均显示缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to compare the performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT in the evaluation of primary and metastatic lesions of gastric cancer. METHODS: Fifty-six patients with histologically proven gastric carcinomas were enrolled in this study, including 45 patients for staging and 11 patients for restaging after surgery. Each patient underwent both [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT within 1 week. The activity of tracer accumulation in lesions was assessed by maximum standardized uptake value (SUVmax) and TBR (lesions SUVmax/ascending aorta SUVmean). Histological workup served as a standard of reference. If tissue diagnosis was not applicable, the follow-up data including the results of laboratory tests and medical imaging could also serve as a reference. RESULTS: [68Ga]Ga-DOTA-FAPI-04 PET/CT was comparable to [18F]FDG on detecting primary tumors and lymph node (LN) metastases, whereas [68Ga]Ga-DOTA-FAPI-04 outperformed [18F]FDG in detecting peritoneal (159 vs. 47, P < 0.001) and bone metastases (64 vs. 55, P = 0.003) by the lesion-based analysis. [68Ga]Ga-DOTA-FAPI-04 showed higher SUVmax (10.3 vs. 8.1, P = 0.004) and TBR (11.6 vs. 5.8, P < 0.001) in primary tumor, and higher TBR in LN involvement (8.0 vs. 3.7, P < 0.001) and peritoneal metastases (8.1 vs. 3.2, P < 0.001), compared with [18F]FDG PET/CT. The specificity and positive predictive value of [68 Ga]Ga-DOTA-FAPI-04 were significantly higher than that of [18F]FDG (100.0% vs. 97.7%, P < 0.001; 100.0% vs. 57.1%, P = 0.001) in determining the LN status. [68Ga]Ga-DOTA-FAPI-04 was comparable to [18F]FDG in evaluating N-staging (47.1% vs. 23.5%, P = 0.282). [68Ga]Ga-DOTA-FAPI-04 PET/CT detected more positive recurrent lesions in all restaging patients and showed clearer tumor delineation. Two patients underwent follow-up [68Ga]Ga-DOTA-FAPI-04 PET/CT scans after chemotherapy, which both showed remission. CONCLUSIONS: [68Ga]Ga-DOTA-FAPI-04 PET/CT can better evaluate primary gastric cancer and metastatic lesions in the peritoneum, abdominal LNs, and bone. Furthermore, [68Ga]Ga-DOTA-FAPI-04 PET/CT provided more information for patients with recurrent disease and had the potential in monitoring response to treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lin R, Lin Z, Chen Z, et al. [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022. PMID: 35462566. doi:10.1007/s00259-022-05799-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。